Treatment with VNP-loaded macrophages upregulated PD-L1 on cancer cells and downregulated PD-1 on tumor-infiltrating CD8+ T cells, potentially increasing tumor sensitivity to PD-1/PD-L1 blockade therapy. The gene discussed is CD8A; the disease is cancer.